INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2025, Number 1

Cardiovasc Metab Sci 2025; 36 (1)

Metformin in the management of non-alcoholic fatty liver disease: current evidence and future perspectives

Flores-Estrada, José Javier; Pinto-García, Luis José; Nájera-García, Nayelli; Marché-Fernández, Osvaldo Alexis; Cáceres-Carranza, Fernando Javier

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD), linked to obesity and type 2 diabetes, affects nearly one billion people globally, with rising prevalence due to both improved diagnostics and increasing incidence. In Mexico, NAFLD prevalence may exceed 50%. A particular study was conducted on 505 young adults, where 47% were at risk for non-alcoholic steatohepatitis (NASH), and 67.8% showed abnormal liver stiffness or confirmed NASH. NAFLD management requires a comprehensive approach, from early-stage lifestyle changes to targeted pharmacological treatments for advanced fibrosis or cirrhosis. Metformin, a widely used diabetes medication, shows promise in NAFLD by improving liver damage markers and insulin resistance and potentially reducing hepatocellular carcinoma risk, though evidence of significant liver histological improvements is limited. This article explores metformin's role in NAFLD treatment, focusing on its potential impact in Mexico and beyond.
  FULL TEXT PDF  

Keywords

metformin non-alcoholic fatty liver disease biomarkers




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • Statement from the Presidency of ANCAM and its Editorial Committee
    2025, Vol.36, Núm. 1
  • Metformin in the management of non-alcoholic fatty liver disease: current...
    2025, Vol.36, Núm. 1
  • Leptin: a description of its intriguing biology. A review. Part I
    2025, Vol.36, Núm. 1
  • The MACARENHA connection: a holistic approach to understand and fight the...
    2025, Vol.36, Núm. 1
  • Coronary artery to right pulmonary artery fistula in an adolescent
    2025, Vol.36, Núm. 1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3

Cardiovascular and Metabolic Science Vol. 36, Num. 1, Enero-Marzo 2025. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 https://www.cardiovascularandmetabolicscience.org.mx/ ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail addresses: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-061316491900-203. ISSN: 2683-2828 versión impresa y 2954-3835 versión electrónica. Ambos otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 04 de abril de 2024.

 

2025     |     https://www.cardiovascularandmetabolicscience.org.mx/